Brief: Camurus Reiterates FY 2026 Outlook
BRIEF-Camurus Reiterates FY 2026 Outlook Nov 5 (Reuters) - Camurus AB CAMX.ST:
Q3 EBIT SEK 322 MILLION
Q3 REVENUE SEK 724 MILLION VERSUS. IBES ESTIMATE SEK 691.2 MILLION
Q3 2026 PRODUCT SALES INCREASED 28% TO MSEK 582
2026 OUTLOOK REITERATED
DURING QUARTER, FDA ACCEPTED RESUBMISSION OF NDA FOR CAM2029 FOR REVIEW IN ACROMEGALY AND OCZYESA WAS APPROVED IN AUSTRALIA
HEALTH CANADA APPROVES OCZYESA XR FOR ACROMEGALY
Source text: ID:nWkr2kJSLq
Further company coverage: CAMX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))